Evrys Bio, Inc.
Publicly observedDoylestown, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Doylestown | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Evrys Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | TM98GAF3Z6Q6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant20 Aug 2021Publicly observed
NIH SBIR/STTR award: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure
USD 961,797.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant20 Aug 2021Publicly observed
NIH SBIR/STTR award: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure
USD 961,797.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jun 2014Publicly observed
NIH SBIR/STTR award: A single antiviral to treat multiple opportunistic infections
USD 978,771.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.